Beclomethasone dipropionate (BDP) is a potent topically active corticosteroid. BDP is hydrolyzed to an active metabolite, beclomethasone 17-monopropionate, by esterase enzymes in the intestinal and bronchial mucosa. Systemic adverse effects are limited by incomplete mucosal absorption and rapid metabolism in the liver.
Since March 2004, we have used oral BDP as initial treatment of GI acute GVHD following RI-CBT instead of systemic corticosteroid. We will review medical, pathological and laboratory records of five patients with GI GVHD who were treated with oral BDP.
Between March 2003 and December 2004, 38 patients with hematological diseases or solid tumors underwent RI-CBT at Toranomon Hospital. Details of transplantation procedures and supportive cares were reported previously. 8 The preparative regimen mainly comprised fludarabine 125 mg/m 2 , melphalan 80 mg/m 2 and 4 Gy total body irradiation. GVHD prophylaxis was cyclosporine 3 mg/kg or tacrolimus 0.03 mg/kg. CMV pp65 antigenemia was monitored weekly after engraftment. If CMV antigenemia exceeded 10/50 000, patients preemptively received ganciclovir 5 mg/kg or foscarnet 30 mg/kg intravenously twice a day. When patients developed pathologically proven GI acute GVHD with or without stage 1 and 2 skin involvement, patients received one enteric-coated cellulose capsule and an aqueous suspension by mouth every 6 h for a total daily dose of 8 mg. Both enteric-coated cellulose capsule and aqueous suspension containing 1 mg BDP powder (Wako Pure Chemical Industries, Ltd, Osaka, Japan) were prepared in our hospital. BDP in the form of aqueous suspension is activated in the stomach and the upper intestine. The enteric-coated capsule dissolves in the small intestine, delivering active drug into the small intestine and the colon. The duration of BDP was at the discretion of the primary physicians. All patients provided written informed consent in accordance with the requirements of the institutional review board. The other patients with grade II-IV acute GVHD were treated with systemic methylprednisolone 0.5-2.0 mg/kg. Response to BDP was determined according to the study by Martin et al.
9
A total of 17 (44.7%) patients developed grade II-IV acute GVHD, and five of them were treated with oral BDP. Their clinical characteristics and outcomes were shown in Table 1 . Responses to BDP included complete response (CR) (n ¼ 3) and progression (n ¼ 2). Acute GVHD had not recurred in the three patients (Cases 1-3) who achieved CR. None of these three patients developed either bacterial or fungal infection, whereas cytomegalovirus enterocolitis was diagnosed in a patient (Case 1). The remaining two patients (Cases 4 and 5) who had not responded to oral BDP were given methylpresonisolone 1-2 mg/kg as a second treatment, and all of them achieved CR. These two patients were complicated with cytomegalovirus enterocolitis during administration of methylprednisolone, and were successfully treated with ganciclovir or foscarnet. As of July 2006, one of the five patients (Case 1) is alive without disease progression. The other four patients died of recurrence (Cases 2, 3 and 4) and chronic GVHD (Case 5).
The present study showed that oral BDP is a useful agent for the treatment of GI acute GVHD following RI-CBT.
When patients with acute GVHD are given systemic corticosteroid, it involves a high risk of bloodstream infection (BSI). We previously reported that 32% of RI-CBT recipients developed BSI within 100 days of transplantation, and that it was associated with systemic use of corticosteroid (relative risk, 43.1). 10 However, none of the five patients developed BSI during and after administration of oral BDP in the present study. Oral BDP causes limited immunosuppression to the systemic organs other than the gut, [4] [5] [6] and the risk of BSI might not be elevated in patients given oral BDP for the treatment of GI acute GVHD.
Considering that three of the five patients achieved CR with oral BDP, it is reasonable to assume that systemic administration of corticosteroid is not requisite for GI acute GVHD, and that oral BDP is occasionally sufficient for its control. However, it should be noted that the remaining two patients failed to achieve CR, and that one of them finally died of chronic GVHD. The two patients with treatment failures (Cases 4 and 5) might have responded to short-course prednisone along with oral BDP, followed by a rapid prednisone taper as reported by McDonald et al. 5 These findings suggest that systemic corticosteroid might have been required for these two patients. Alternatively, oral BDP at a dose of 8 mg/day might have been suboptimal in these patients. Further studies are warranted to clarify the eligibility of oral BDP, and its optimal dose for the treatment of GI acute GVHD.
In conclusion, the present study demonstrated the feasibility of oral BDP in the treatment of GI acute GVHD following RI-CBT. It suppresses allogeneic immune responses in the gut without causing significant immunosuppression. However, this study is too small to draw a definite conclusion on oral BDP, and we are now planning a large-scale prospective study. 
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